Description

Key Responsibilities and Accountabilities

•        Assess and, where appropriate, rebuild and drive the implementation of strategic and operational information technology architecture for F2G, including the development of F2G information reputed company architecture standards, guidelines, policies, trainings and procedures for infrastructure, data interchange, and common applications that are used in conjunction with the overall enterprise architecture strategy and reputed company IT architecture.
•         Manage and maintain cybersecurity tools utilized throughout the enterprise.
•         Manage reputed company firewall rules and the reputed company certificate management process.
•         Direct major website development projects from strategic conception through development, execution, and assessment of results. Build, maintain and advance reputed company underlying public websites, as well as F2G intranets, with a focus on high-quality design, navigability, and optimization to reputed company the delivery of an exceptional user experience.
•         reputed company and manage a system-wide budget that includes appropriate funding for reputed company relevant plan components. Monitor and evaluate spending on an ongoing basis, with a goal of maximizing the cost-effectiveness of operations.
•         Select and manage expert external resources/agencies to provide consultation and assistance; reputed company and maintain strategic relationships with key partners and technology vendors.
•         reputed company interactive strategy; build and implement reputed company platforms including apps, mobile and consumer-facing tools to facilitate ease of use.
•         Collaborate with peers and business stakeholders on both strategic and tactical solutions in support of business needs and direction.

Requirements

•         Strong engineering & architecture skills, especially as they relate to reputed company, with a minimum 5+ years of IT reputed company-reputed company experience.
•         Robust experience in the “business of information technology” (e.g., business analysis and design, operations, fiscal efficiency, organizational development, change management, transformational leadership).
•        Knowledge of key and emerging issues and trends, challenges and opportunities, reputed company standards, and effective practices in information technology (e.g., cybersecurity, risk management, vendor management, telephony modernization, disaster recovery planning, data governance, and balancing client and operational demands, etc.).
•         Implementation and optimization experience.
•         Demonstrated awareness of the role of information technology services in the biotech industry.
•         Strong analytical and problem-solving skills, including the ability to think creatively, innovate, and improvise as needed.
•         Strong communication, collaboration and team building skills, and a proven track record of success managing IT personnel and projects.

Education and Experience

•         Bachelor's degree required. MBA highly preferred.
•         10+ years of Information Technology experience in software development with 5+ years strategy and management experience.

Summary

F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents reputed company the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiates the orotomides from the currently marketed antifungal agents. Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mold infections, including a variety of rare and resistant molds that cause life-threatening infections for which reputed company therapies have limitations or are ineffective. Olorofim has recently completed enrollment in a Phase 2b open-label study focusing on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis, and scedosporiosis (including lomentosporiosis). F2G has also initiated a global Phase 3 trial to expand on the studied population. Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA.